Sirtuin Modulator Companies for Alzheimer's Disease

Overview

This category page covers biotechnology and pharmaceutical companies developing sirtuin-targeted therapies for Alzheimer's disease. Sirtuins (SIRT1-7) are NAD+-dependent deacetylases that play critical roles in mitochondrial function, DNA repair, stress resistance, and cellular homeostasis—all processes impaired in Alzheimer's disease.

For the main mechanism page, see [SIRT1 Signaling Pathway in Alzheimer's Disease](/mechanisms/sirt1-alzheimer-pathway).

Therapeutic Approaches

SIRT1 Activation

• Direct SIRT1 activators (resveratrol, synthetic compounds like SRT2104)
• NAD+ precursors (nicotinamide riboside, NMN) that enhance SIRT1 activity indirectly
• Mechanisms: PGC-1α deacetylation → mitochondrial biogenesis; FOXO deacetylation → stress resistance; tau deacetylation → reduced aggregation; NF-κB deacetylation → reduced neuroinflammation

SIRT2 Inhibition

• SIRT2 inhibitors may protect against AD progression
• Target α-synuclein toxicity (relevant for comorbid PD/LBD)
• Reduce inflammatory responses

SIRT3 Modulation

• Mitochondrial sirtuin targeting
• SOD2 activation → reduced oxidative stress
• IDH2 activation → improved mitochondrial metabolism
• Epigenetic regulation of mitochondrial genes

Company Directory

Major Pharmaceutical Companies

| Company | Focus | Programs | Status |
|--------|-------|----------|--------|
| GSK | SIRT1 direct activators | SRT2104 (historical), SRT3025 | Historical/Clinical |

Biotechnology Companies

Overview

This category page covers biotechnology and pharmaceutical companies developing sirtuin-targeted therapies for Alzheimer's disease. Sirtuins (SIRT1-7) are NAD+-dependent deacetylases that play critical roles in mitochondrial function, DNA repair, stress resistance, and cellular homeostasis—all processes impaired in Alzheimer's disease.

For the main mechanism page, see [SIRT1 Signaling Pathway in Alzheimer's Disease](/mechanisms/sirt1-alzheimer-pathway).

Therapeutic Approaches

SIRT1 Activation

• Direct SIRT1 activators (resveratrol, synthetic compounds like SRT2104)
• NAD+ precursors (nicotinamide riboside, NMN) that enhance SIRT1 activity indirectly
• Mechanisms: PGC-1α deacetylation → mitochondrial biogenesis; FOXO deacetylation → stress resistance; tau deacetylation → reduced aggregation; NF-κB deacetylation → reduced neuroinflammation

SIRT2 Inhibition

• SIRT2 inhibitors may protect against AD progression
• Target α-synuclein toxicity (relevant for comorbid PD/LBD)
• Reduce inflammatory responses

SIRT3 Modulation

• Mitochondrial sirtuin targeting
• SOD2 activation → reduced oxidative stress
• IDH2 activation → improved mitochondrial metabolism
• Epigenetic regulation of mitochondrial genes

Company Directory

Major Pharmaceutical Companies

| Company | Focus | Programs | Status |
|--------|-------|----------|--------|
| GSK | SIRT1 direct activators | SRT2104 (historical), SRT3025 | Historical/Clinical |

Biotechnology Companies

| Company | Focus | Programs | Page |
|--------|-------|----------|------|
| ChromaDex | NAD+ precursors | NR-002, Tru NIAGEN | [ChromaDex](/companies/chromadex) |
| Life Biosciences | SIRT1 activator | LB-SIRT1 program | [Life Biosciences](/companies/life-biosciences) |
| Elysium Health | NAD+ supplements | Basis | — |
| Vivoryon Therapeutics | SIRT1 modulators | PQ912 | [Vivoryon](/companies/vivoryon) |

Pipeline Overview

Clinical Stage Programs

| Company | Compound | Target | Mechanism | Phase | Indication |
|---------|----------|--------|-----------|-------|------------|
| ChromaDex | NR-002 | SIRT1 (indirect) | NAD+ augmentation | Phase 2 | Alzheimer's disease |
| GSK (historical) | SRT2104 | SIRT1 | Direct activation | Phase 2 | Alzheimer's disease |
| Life Biosciences | LB-SIRT1 | SIRT1 | Direct activation | Discovery | Alzheimer's disease |
| Vivoryon | PQ912 | SIRT1 | Direct activation | Phase 2 | Alzheimer's disease |

Key Mechanisms

• [SIRT1 Signaling Pathway in Alzheimer's Disease](/mechanisms/sirt1-alzheimer-pathway)
• [NAD+ Metabolism Pathway](/mechanisms/nad-metabolism-pathway-neurodegeneration)
• [Mitochondrial Biogenesis in Neurodegeneration](/mechanisms/mitochondrial-biogenesis-neurodegeneration)
• [Sirtuin Signaling Pathway](/mechanisms/sirtuin-signaling-pathway)

Related Therapeutics

• [Sirtuin Modulators](/therapeutics/sirtuin-modulators)
• [NAD+ Boosters for Neurodegeneration](/therapeutics/nad-boosters-neurodegeneration)
• [Resveratrol and Neurodegeneration](/therapeutics/resveratrol-neurodegeneration)

Market Landscape

The sirtuin modulator field for Alzheimer's disease has evolved through several phases:

Investment Trends

• Major pharma (GSK) has reduced direct SIRT1 activator investment
• Biotech focus on NAD+ augmentation (ChromaDex, Elysium)
• Academic/industry partnerships for biomarker development
• Growing interest in combination therapies (SIRT1 + other mechanisms)

Research Gaps

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [SIRT1 Signaling Pathway in Alzheimer's Disease](/mechanisms/sirt1-alzheimer-pathway)
• [Parkinson's Disease Sirtuin Modulator Companies](/companies/pd-sirtuin-modulator-companies)
• [Investment Landscape: Sirtuin Therapeutics](/investment/sirtuin-therapeutics-neurodegeneration)
• [AD Pipeline](/companies/ad-pipeline)

References

Pathway Diagram

The following diagram shows the key molecular relationships involving Sirtuin Modulator Companies for Alzheimer's Disease discovered through SciDEX knowledge graph analysis: